Literature DB >> 20002102

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.

T V Zanelati1, C Biojone, F A Moreira, F S Guimarães, Sâmia R L Joca.   

Abstract

BACKGROUND AND
PURPOSE: Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa that induces anxiolytic- and antipsychotic-like effects in animal models. Effects of CBD may be mediated by the activation of 5-HT(1A) receptors. As 5-HT(1A) receptor activation may induce antidepressant-like effects, the aim of this work was to test the hypothesis that CBD would have antidepressant-like activity in mice as assessed by the forced swimming test. We also investigated if these responses depended on the activation of 5-HT(1A) receptors and on hippocampal expression of brain-derived neurotrophic factor (BDNF). EXPERIMENTAL APPROACH: Male Swiss mice were given (i.p.) CBD (3, 10, 30, 100 mg*kg(-1)), imipramine (30 mg*kg(-1)) or vehicle and were submitted to the forced swimming test or to an open field arena, 30 min later. An additional group received WAY100635 (0.1 mg*kg(-1), i.p.), a 5-HT(1A) receptor antagonist, before CBD (30 mg*kg(-1)) and assessment by the forced swimming test. BDNF protein levels were measured in the hippocampus of another group of mice treated with CBD (30 mg*kg(-1)) and submitted to the forced swimming test. KEY
RESULTS: CBD (30 mg*kg(-1)) treatment reduced immobility time in the forced swimming test, as did the prototype antidepressant imipramine, without changing exploratory behaviour in the open field arena. WAY100635 pretreatment blocked CBD-induced effect in the forced swimming test. CBD (30 mg*kg(-1)) treatment did not change hippocampal BDNF levels. CONCLUSION AND IMPLICATIONS: CBD induces antidepressant-like effects comparable to those of imipramine. These effects of CBD were probably mediated by activation of 5-HT(1A) receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002102      PMCID: PMC2823358          DOI: 10.1111/j.1476-5381.2009.00521.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  69 in total

Review 1.  Colorimetric protein assay techniques.

Authors:  C V Sapan; R L Lundblad; N C Price
Journal:  Biotechnol Appl Biochem       Date:  1999-04       Impact factor: 2.431

2.  Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors.

Authors:  N Haddjeri; P Blier; C de Montigny
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

Review 3.  Do patients use marijuana as an antidepressant?

Authors:  A J Gruber; H G Pope; M E Brown
Journal:  Depression       Date:  1996

4.  Distribution and characterization of anandamide amidohydrolase in mouse brain and liver.

Authors:  K Watanabe; H Ogi; S Nakamura; Y Kayano; T Matsunaga; H Yoshimura; I Yamamoto
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

5.  Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats.

Authors:  J M Brezun; A Daszuta
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

6.  Activation of serotonergic 5-HT1A receptor reduces Ca(2+)- and glutamatergic receptor-evoked arachidonic acid and No/cGMP release in adult hippocampus.

Authors:  J Strosznajder; M Chalimoniuk; M Samochocki
Journal:  Neurochem Int       Date:  1996-04       Impact factor: 3.921

7.  Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity.

Authors:  C A Stockmeier; L A Shapiro; G E Dilley; T N Kolli; L Friedman; G Rajkowska
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

Review 8.  Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments.

Authors:  V Di Marzo; L De Petrocellis; T Bisogno; D Melck
Journal:  Lipids       Date:  1999       Impact factor: 1.880

9.  Comparative receptor binding analyses of cannabinoid agonists and antagonists.

Authors:  B F Thomas; A F Gilliam; D F Burch; M J Roche; H H Seltzman
Journal:  J Pharmacol Exp Ther       Date:  1998-04       Impact factor: 4.030

10.  Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors.

Authors:  F Petitet; B Jeantaud; M Reibaud; A Imperato; M C Dubroeucq
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

View more
  99 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

2.  Comment on: "Anxiogenic-like effects of chronic cannabidiol administration in rats" (Elbatsh MM, Assareh N, Marsden CA, Kendall DA, Psychopharmacology 2012).

Authors:  Anand Gururajan
Journal:  Psychopharmacology (Berl)       Date:  2012-07-04       Impact factor: 4.530

3.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

4.  Fatty acid-binding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

Authors:  Matthew W Elmes; Martin Kaczocha; William T Berger; KwanNok Leung; Brian P Ralph; Liqun Wang; Joseph M Sweeney; Jeremy T Miyauchi; Stella E Tsirka; Iwao Ojima; Dale G Deutsch
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

5.  Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.

Authors:  Adrián Viudez-Martínez; María S García-Gutiérrez; Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-07-01       Impact factor: 8.739

6.  Cannabidiol in Anxiety and Sleep: A Large Case Series.

Authors:  Scott Shannon; Nicole Lewis; Heather Lee; Shannon Hughes
Journal:  Perm J       Date:  2019

7.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

8.  Amygdala-hippocampal innervation modulates stress-induced depressive-like behaviors through AMPA receptors.

Authors:  Hui Ma; Chenyang Li; Jinpeng Wang; Xiaochen Zhang; Mingyue Li; Rong Zhang; Zhuo Huang; Yong Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

9.  Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.

Authors:  Aimee L McRae-Clark; Nathaniel L Baker; Kevin M Gray; Therese K Killeen; Amanda M Wagner; Kathleen T Brady; C Lindsay DeVane; Jessica Norton
Journal:  Drug Alcohol Depend       Date:  2015-08-25       Impact factor: 4.492

10.  Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats.

Authors:  E M Rock; L A Parker
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.